|
3 Companies |
|
2 Products |
|
2 Products |
|
0 Mechanisms of Action |
|
1 Trial |
|
18 News |
|
- | Trial completion: The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease (clinicaltrials.gov) - Jan 25, 2018
P2, N=20, Completed, Sponsor: Brainsway
Recruiting --> Completed
- | Cabaletta (trehalose) / Seelos Therap
Trial completion: Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease (clinicaltrials.gov) - Nov 22, 2016
P2, N=15, Completed, Sponsor: Bioblast Pharma Ltd.
Recruiting --> Completed Active, not recruiting --> Completed
- | Cabaletta (trehalose) / Seelos Therap
Enrollment closed, Enrollment change: Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease (clinicaltrials.gov) - Aug 19, 2016
P2, N=15, Active, not recruiting, Sponsor: Bioblast Pharma Ltd.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=20 --> 15
- Cabaletta (trehalose) / Seelos Therap
Trial primary completion date: Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease (clinicaltrials.gov) - Aug 22, 2015
P2, N=20, Recruiting, Sponsor: Bioblast Pharma Ltd.
Recruiting --> Active, not recruiting | N=20 --> 15 Trial primary completion date: Feb 2015 --> Oct 2016
- | Cabaletta (trehalose) / Seelos Therap
Enrollment open: Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease (clinicaltrials.gov) - Nov 18, 2014
P2, N=20, Recruiting, Sponsor: Bioblast Pharma Ltd.
Trial primary completion date: Feb 2015 --> Oct 2016 Not yet recruiting --> Recruiting
- | Enrollment open: The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease (clinicaltrials.gov) - Sep 16, 2014
P2, N=20, Recruiting, Sponsor: Brainsway
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | dalfampridine / Generic mfg.
Trial completion: Dalfampridine and Gait in Spinocerebellar Ataxias (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=20, Completed, Sponsor: University of Florida
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Cabaletta (trehalose) / Seelos Therap
New P2 trial: Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease (clinicaltrials.gov) - May 26, 2014
P2, N=20, Not yet recruiting, Sponsor: Bioblast Pharma Ltd.
- | New P2 trial: The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease (clinicaltrials.gov) - Jan 15, 2014
P2, N=20, Not yet recruiting, Sponsor: Brainsway
- dalfampridine / Generic mfg.
Enrollment change: Dalfampridine and Gait in Spinocerebellar Ataxias (clinicaltrials.gov) - Oct 10, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed N=30 --> 20
- dalfampridine / Generic mfg.
Enrollment closed: Dalfampridine and Gait in Spinocerebellar Ataxias (clinicaltrials.gov) - Oct 10, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: University of Florida
N=30 --> 20 Recruiting --> Active, not recruiting
- | lithium carbonate ER / Generic mfg.
Trial completion: Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3 (clinicaltrials.gov) - Jan 28, 2013
P2/3, N=62, Completed, Sponsor: Hospital de Clinicas de Porto Alegre
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- sodium phenylbutyrate / Generic mfg.
Trial withdrawal: Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3 (clinicaltrials.gov) - Aug 14, 2012
P2, N=0, Withdrawn, Sponsor: Hospital de Clinicas de Porto Alegre
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- sodium phenylbutyrate / Generic mfg.
Enrollment change: Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3 (clinicaltrials.gov) - Aug 14, 2012
P2, N=0, Withdrawn, Sponsor: Hospital de Clinicas de Porto Alegre
Not yet recruiting --> Withdrawn N=20 --> 0
- Chantix (varenicline) / Pfizer
Trial completion: Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3 (clinicaltrials.gov) - Jun 14, 2012
P2, N=20, Completed, Sponsor: University of South Florida
N=20 --> 0 Active, not recruiting --> Completed